Tag: dea

14 GOP Congressional Lawmakers Tell DEA To Keep Marijuana In Schedule I And ‘Reject’ Top Health Agency’s Recommendation

A coalition of 14 Republican congressional lawmakers is urging the Drug Enforcement Administration (DEA) to “reject” the top federal health agency’s recommendation to reschedule marijuana and instead keep it in the most restrictive category under the Controlled Substances Act (CSA).

In a letter sent to DEA Administrator Anne Milgram on Monday, Sen. James Lankford (R-OK) and Rep. Pete Sessions (R-TX) led a dozen other colleagues in both chambers in arguing that any decision to reschedule cannabis “should be based on proven facts and science—not popular opinion, changes in state laws, or the preferred policy of an administration.”

Of course, the U.S. Department of Health and Human Services (HHS) has repeatedly emphasized that its review into marijuana scheduling, directed by President Joe Biden late last year, was science-based. And after 11 months of investigation, it has recommended that marijuana be placed in Schedule III. Milgram has also made clear that DEA’s review will follow the science.

The eight GOP senators and six House members evidently distrust the motives behind the HHS recommendation, however, and they argued in the letter, first reported by The Washington Stand, that the current “research, science, and trends support the case that marijuana should remain a Schedule I drug.”

They pointed to National Institute on Drug Abuse (NIDA) data on rates of cannabis use disorder and raised concerns about increased THC potency of marijuana products, stating that these “facts indicate that marijuana has a high potential for abuse and that the risk is only increasing.”  For what it’s worth, NIDA also reportedly signed off the HHS rescheduling recommendation before it was sent to DEA.

Keep reading

Medical Marijuana Company Slams DEA In Lawsuit Alleging Extreme Delays To Cannabis Research Licensing

A company focused on developing marijuana-derived pharmaceuticals is suing the Drug Enforcement Administration (DEA) over what it calls “exponential delays” in the agency’s process for granting licenses to grow cannabis for medical research.

Rhode Island-based MMJ BioPharma Cultivation Inc. filed a petition for a writ of mandamus in the U.S. Court of Appeals for the D.C. Circuit on Friday, alleging that DEA’s yearslong licensing application process has hamstrung the company’s business and stymied innovation that could benefit patients. It’s asking the federal court to compel the agency to act.

“Despite beginning this process in November of 2017,” the company says in the lawsuit, “MMJ has been unable to conduct the research that it was created to do.”

MMJ is working to produce a gel capsule containing cannabis extracts, which it says is intended to treat multiple sclerosis and Huntington’s disease. While it previously received DEA authorization to import marijuana into the U.S. from Canada, MMJ later applied for permission to cultivate cannabis in-house for research and development purposes.

“This registration is essential to MMJ’s ability to conduct FDA-sanctioned clinical trials,” the company says, “because without the ability to cultivate their own marijuana, they are unable to produce the proper compound.”

MMJ asserts that DEA’s pre-registration investigation for the license application began in June 2021 and lasted through the following October. “At the end of the visit, the diversion investigator informed MMJ that they would return to the DEA office, ‘write up’ the report, and submit the report to their group supervisor who would then submit those findings to DEA Headquarters for a final determination,” the suit says.

But according to the petition, no final determination ever came. “Despite numerous attempts to follow-up and check the status of the registration approval determinations for manufacturing, DEA personnel have expressed to MMJ that they have not yet made final determinations and they have no idea when that determination will be made,” it says.

Keep reading

Thanks for nothing, DEA. Fifty years later, drugs are deadlier and more abundant than ever

As of this week, the United States has “enjoyed” half a century under the thumb of the Drug Enforcement Administration (DEA), a wing of the Department of Justice established in 1973 by former President Richard Nixon. Instead of truly addressing the deepening drug problem in the U.S., the DEA has worsened public health outcomes related to drug use, promoted racially stigmatizing policies, stomped on civil liberties and burned stacks of cash in a vain effort to control the uncontrollable.

There’s no denying the drug situation in the U.S. is dire. Approximately 1 million people have died of overdoses since 1999, many of these deaths driven by powerful opioids like illicit fentanyl and its many analogs. Nonetheless, polydrug use — the mixing of multiple substances — is a far more lethal combination than any drug on its own, as well as the true underbelly of this drug crisis disaster.

Despite decades of increased funding, more seizures and more policing, the DEA cannot seem to make a dent in this crisis. The body count from overdoses continues to rise, and there’s no end to the flow of drugs into the U.S.

Keep reading

After 50 Years, the DEA Is Still Losing the War on Drugs

“COCAINE UNIQUELY FITS THE FAST-PACED AMERICAN LIFESTYLE,” reads a caption for an exhibit at the Drug Enforcement Administration (DEA) Museum in Arlington, Virginia. “The Federal Bureau of Narcotics considered cocaine a nearly defeated drug,” it continues. “However, cocaine use rebounded, reaching its highest use level ever at the end of the 20th century.” It’s an oddly candid observation to find in a place you’d expect to celebrate the federal agency whose mission is to “enforce the controlled substances laws and regulations of the United States.”

The DEA is celebrating its 50th anniversary this year, marking half a century of abject mission failure. During five decades as a bottomless money pit that has destroyed countless lives while targeting Americans for personal choices and peaceful transactions, the agency’s annual budget has ballooned from $75 million to $3.2 billion. The DEA currently operates 90 foreign offices in 67 countries. It has seized billions of dollars in drugs, cash, vehicles, and real property. Since 1986, it has arrested more than 1 million people for manufacturing, distributing, or possessing illegal drugs. Yet in 2021, the Centers for Disease Control and Prevention (CDC) counted more than 107,600 drug-related deaths—an all-time high. The DEA’s own data show a steady, gradual decline in price and rise in purity for most street drugs since the 1980s. The DEA’s 2020 National Drug Threat Assessment notes that methamphetamine “purity and potency remain high while prices remain relatively low,” and cocaine availability remains steady.

While there are some reasons to believe Americans may finally have tired of the DEA’s oversized role in their lives, the agency remains a powerful force. To understand what went wrong—and why it will keep going wrong—you have to go back to the agency’s origins.

Keep reading

Drug Busts Are Linked to More Overdoses and Deaths

As the Drug Enforcement Administration (DEA) celebrates its 50th birthday, new research highlights how counterproductive its mission is. Published in the American Journal of Public Health, the research links drug busts to a spike in overdoses in nearby areas.

The cross-university team of researchers started out with this hypothesis: “Law enforcement efforts to disrupt local drug markets by seizing opioids or stimulants are associated with increased spatiotemporal clustering of overdose events in the surrounding geographic area.”

To test this hypothesis, they looked at data from Marion County, Indiana, on drug seizures and overdoses—including fatal overdoses, emergency medical calls for nonfatal overdoses, and naloxone administration—in 2020 and 2021. Marion County is the largest county in Indiana and contains the state capital, Indianapolis.

They found a significant association between “opioid-related law enforcement drug seizures” and an increase in drug overdoses in surrounding areas (that is, within 100, 250, and 500 meters). This association held at one week, two weeks, and three weeks from the drug bust data.

“For example, the expected number of fatal overdoses within 500 meters and 21 days of opioid-related drug seizures ranged from 18.0 to 22.7 per 100 drug seizures, so the observed rate of 23.6 was higher than expected,” the paper states.

Stimulant-related drug seizures were also associated with an increase in drug overdoses, albeit to a lesser extent than with opioid-related drug seizures. The significant association here only held “at a distance of 100 meters within 7 days,” and was stronger for nonfatal overdoses.

During the two-year study period, there were 2,110 opioid-related and 3,039 stimulant-related seizures—an average of seven per day. There were 1,171 overdose deaths recorded during that period (an average of 1.6 per day) and 12,590 nonfatal overdoses (an average of 17.2 per day).

“Supply-side enforcement interventions and drug policies should be further explored to determine whether they exacerbate an ongoing overdose epidemic and negatively affect the nation’s life expectancy,” the researchers suggest.

Keep reading

Ohio State receives first-ever DEA license to grow psychedelic mushrooms for research

Ohio State University is about to grow psychedelic mushrooms.

For scientific research, people.

Ohio State, alongside the mental health and wellness research and development company Inner State Inc., was awarded the first-ever license by the U.S. Drug Enforcement Agency to grow whole psilocybin mushrooms. The mushrooms will be used in the study of mental health treatment capabilities with naturally grown psychedelic mushrooms.

“This license is a major milestone not only for Inner State and Ohio State, but for the entire field of psychedelic research,” Inner State CEO Ashley Walsh said Wednesday in a news release.

The license allows Ohio State and Inner State to cultivate psilocybin mushrooms for research purposes only. All research will be conducted in a federally sanctioned and secured grow house in accordance with strict DEA regulations and guidelines.

“By combining cutting-edge techniques in genomics and metabolomics, we have the opportunity to obtain a high-resolution picture of the chemical diversity of mushrooms that have remained difficult to study for several decades,” according to Ohio State researchers Dr. Jason Slot and Dr. Kou-San Ju.

Keep reading

New Jersey factory imports cocaine plant that flavors Coca-Cola thanks to DEA arrangement

Guess you really can’t beat the real thing.

Coca-Cola gets its iconic taste thanks in part to a chemical processing factory in a sleepy New Jersey neighborhood that has the country’s only license to import the plant used to make cocaine.

The Maywood-based facility, now managed by the Stepan Company, has been processing coca leaves for the soft-drink giant for more than a century and had its license to import them renewed by the Drug Enforcement Agency earlier this year.

The coca leaves are used to create a “decocainized” ingredient for the soda and the leftover byproduct is sold to the opioid manufacturing company Mallinckrodt, which uses the powder to make a numbing agent for dentists, DailyMail reported.

It is unclear how much coca leaves the Stepan Company imports annually, although the New York Times reported in 1988 that it brought in between 56 and 588 metric tons of coca leaves from Peru and Bolivia each year, citing DEA figures.

Keep reading

Inside the Scandal That Took Down the DEA’s ‘Cowboy’ Chief in Mexico

Relations between the U.S. and Mexico were extremely tense when the DEA’s top boss in Mexico City decided to throw himself a birthday party. It was late October of 2020, and Mexico’s president was furious over the DEA’s arrest of a top military general accused of cartel corruption. But at the fiesta, the mood was jovial. There was drinking and food and a mariachi band to entertain the guests.

The attendees included several high-ranking Mexican officials, along with a few bigwigs from other U.S. law enforcement agencies. At least one person left wondering how the host, who was celebrating his 50th birthday, managed to score a taxpayer-funded house so large and outside the zones typically authorized for housing for senior U.S. officials in Mexico City. One person described the house as a “mega-mansion.”

The party was one of several events that contributed to the downfall of regional director Nick Palmeri, who quietly retired from the DEA last year one day before he was due to be fired. Parts of his undoing, including allegedly improper meetings with defense attorneys who represent cartel members, have recently been made public. But there’s far more to the story, including bitter infighting at the highest levels of the DEA, allegedly

Keep reading

This Couple Died by Suicide After the DEA Shut Down Their Pain Doctor

It was a Tuesday in early November when federal agents from the Drug Enforcement Administration paid a visit to the office of Dr. David Bockoff, a chronic pain specialist in Beverly Hills. It wasn’t a Hollywood-style raid—there were no shots fired or flash-bang grenades deployed—but the agents left behind a slip of paper that, according to those close to the doctor’s patients, had consequences just as deadly as any shootout.

On Nov. 1, the DEA suspended Bockoff’s ability to prescribe controlled substances, including powerful opioids such as fentanyl. While illicit fentanyl smuggled across the border by Mexican cartels has fueled a record surge in overdoses in recent years, doctors still use the pharmaceutical version during surgeries and for soothing the most severe types of pain. But amid efforts to shut down so-called “pill mills” and other illegal operations, advocates for pain patients say the DEA has gone too far, overcorrecting to the point that people with legitimate needs are blocked from obtaining the medication they need to live without suffering. 

One of Bockoff’s patients who relied on fentanyl was Danny Elliott, a 61-year-old native of Warner Robins, Georgia. In March 1991, Elliott was nearly electrocuted to death when a water pump he was using to drain a flooded basement malfunctioned, sending high-voltage shocks through his body for nearly 15 minutes until his father intervened to save his life. Elliott was never the same after the accident, which left him with debilitating, migraine-like headaches. Once a class president and basketball star in high school, he found himself spending days on end in a darkened bedroom, unable to bear sunlight or the sound of the outdoors. 

“I have these sensations like my brain is loose inside my skull,” Elliott told me in 2019, when I first interviewed him for the VICE News podcast series Painkiller. “If I turn my head too quickly, left or right, it feels like my brain sloshes around. Literally my eyes burn deep into my skull. My eyes hurt so bad that it hurts to blink.”

Keep reading

DEA’s most corrupt agent: Parties, sex amid ‘unwinnable war’

José Irizarry accepts that he’s known as the most corrupt agent in U.S. Drug Enforcement Administration history, admitting he “became another man” in conspiring with Colombian cartels to build a lavish lifestyle of expensive sports cars, Tiffany jewels and paramours around the world.

But as he used his final hours of freedom to tell his story to The Associated Press, Irizarry says he won’t go down for this alone, accusing some long-trusted DEA colleagues of joining him in skimming millions of dollars from drug money laundering stings to fund a decade’s worth of luxury overseas travel, fine dining, top seats at sporting events and frat house-style debauchery.

The way Irizarry tells it, dozens of other federal agents, prosecutors, informants and in some cases cartel smugglers themselves were all in on the three-continent joyride known as “Team America” that chose cities for money laundering pick-ups mostly for party purposes or to coincide with Real Madrid soccer or Rafael Nadal tennis matches. That included stops along the way in VIP rooms of Caribbean strip joints, Amsterdam’s red-light district and aboard a Colombian yacht that launched with plenty of booze and more than a dozen prostitutes.

“We had free access to do whatever we wanted,” the 48-year-old Irizarry told the AP in a series of interviews before beginning a 12-year federal prison sentence. “We would generate money pick-ups in places we wanted to go. And once we got there it was about drinking and girls.”

Keep reading